Post-transplantation lymphoproliferative disorder (PTLD) twenty years after heart transplantation: a case report and review of the literature

被引：0
作者：
Petros D. Grivas
机构：
[1] Hahnemann University Hospital/Drexel University College of Medicine,Department of Internal Medicine
来源：
Medical Oncology | 2011年 / 28卷
关键词：
Post-transplantation lymphoproliferative disorder; Diffuse large B-cell lymphoma; Epstein–Barr virus; Rituximab; Chemotherapy; Immunosuppression;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
We report a 62-year-old man who developed biopsy-proven post-transplantation lymphoproliferative disorder (PTLD) 20 years after receiving a heart transplant while being treated with immunosuppressive agents. The patient presented with large retroperitoneal and intestinal wall masses that caused partial gastrointestinal stenosis. Monoclonal antibody against CD20 in conjunction with chemotherapy and tapering of the immunosuppressive regimen was instituted, resulting in objective response of the disease bulk. To the best of our knowledge, this is the second reported case of PTLD 20 years after heart transplantation.
引用
收藏
页码：829 / 834
页数：5
相关论文
共 68 条
[21]  
Swinnen LJ(2003)Epstein-Barr virus (EBV)-positive lymphoproliferations in post-transplant patients show immunoglobulin V gene mutation patterns suggesting interference of EBV with normal B cell differentiation processes Eur J Immunol 33 1593-1602
[22]  
Fischer RI(1995)The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family Cell 80 389-399
[23]  
Opel ZG(2004)Post-transplant lymphoproliferative disorders. Molecular analysis of histogenesis and pathogenesis Minerva Med 95 53-64
[24]  
Dohler G(2005)Histogenetic phenotypes of B cells in posttransplant lymphoproliferative disorders by immunohistochemical analysis correlate with transplant type: solid organ vs hematopoietic stem cell transplantation Am J Clin Pathol 123 104-112
[25]  
Keever-Taylor CA(1999)Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD task force and the mayo clinic organized international consensus development meeting Transplantation 68 1517-1525
[26]  
Ciancio G(2001)The role of antiviral and immunoglobulin therapy in the prevention of Epstein-Barr virus infection and post-transplant lymphoproliferative disease following solid organ transplantation Transpl Infect Dis 3 97-103
[27]  
Cohen JI(2003)Pathogenic roles for Epstein-Barr virus (EBV) gene products in EBV-associated proliferative disorders Crit Rev Oncol Hematol 45 1-36
[28]  
Schulz TF(1998)Interferon-alpha treatment in post-transplant lymphoproliferative disorder in recipients of solid organ transplants Transplantation 66 1770-1779
[29]  
Yates J(2006)Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study Blood 107 3053-3057
[30]  
Warren N(2007)Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution Ann Hematol 86 599-607
1234567